ABVX
Price
$135.98
Change
-$3.92 (-2.80%)
Updated
Jul 13 closing price
Capitalization
12.2B
69 days until earnings call
Intraday BUY SELL Signals
DYN
Price
$23.64
Change
+$0.22 (+0.94%)
Updated
Jul 13 closing price
Capitalization
3.91B
16 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABVX vs DYN

ABVX vs DYN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABVX vs. DYN commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABVX is a Buy and DYN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (ABVX: $135.98 vs. DYN: $23.64)
Brand notoriety: ABVX and DYN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABVX: 22% vs. DYN: 64%
Market capitalization -- ABVX: $12.2B vs. DYN: $3.91B
ABVX [@Biotechnology] is valued at $12.2B. DYN’s [@Biotechnology] market capitalization is $3.91B. The market cap for tickers in the [@Biotechnology] industry ranges from $121.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABVX’s FA Score shows that 0 FA rating(s) are green whileDYN’s FA Score has 1 green FA rating(s).

  • ABVX’s FA Score: 0 green, 5 red.
  • DYN’s FA Score: 1 green, 4 red.
According to our system of comparison, DYN is a better buy in the long-term than ABVX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABVX’s TA Score shows that 6 TA indicator(s) are bullish while DYN’s TA Score has 6 bullish TA indicator(s).

  • ABVX’s TA Score: 6 bullish, 4 bearish.
  • DYN’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, DYN is a better buy in the short-term than ABVX.

Price Growth

ABVX (@Biotechnology) experienced а -5.56% price change this week, while DYN (@Biotechnology) price change was +3.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.21%. For the same industry, the average monthly price growth was +7.25%, and the average quarterly price growth was +1806.27%.

Reported Earning Dates

ABVX is expected to report earnings on Sep 21, 2026.

DYN is expected to report earnings on Jul 30, 2026.

Industries' Descriptions

@Biotechnology (-3.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABVX($12.2B) has a higher market cap than DYN($3.91B). DYN YTD gains are higher at: 20.859 vs. ABVX (0.834). ABVX has higher annual earnings (EBITDA): -298.47M vs. DYN (-439.22M). DYN has more cash in the bank: 972M vs. ABVX (492M). ABVX has less debt than DYN: ABVX (1.45M) vs DYN (169M). ABVX (0) and DYN (0) have equivalent revenues.
ABVXDYNABVX / DYN
Capitalization12.2B3.91B312%
EBITDA-298.47M-439.22M68%
Gain YTD0.83420.8594%
P/E RatioN/AN/A-
Revenue00-
Total Cash492M972M51%
Total Debt1.45M169M1%
TECHNICAL ANALYSIS
Technical Analysis
ABVXDYN
RSI
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
85%
Advances
ODDS (%)
N/A
Bullish Trend 18 days ago
83%
Declines
ODDS (%)
Bearish Trend 1 day ago
80%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ABVX
Daily Signal:
Gain/Loss:
DYN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ESEA71.321.11
+1.58%
Euroseas Ltd
GNRC226.95-6.99
-2.99%
Generac Holdings
BCRX9.91-0.54
-5.17%
BioCryst Pharmaceuticals
AEMD0.67-0.04
-5.51%
Aethlon Medical Inc.
RNTX0.91-0.07
-7.40%
Rein Therapeutics Inc

ABVX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABVX has been loosely correlated with IMNN. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ABVX jumps, then IMNN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABVX
1D Price
Change %
ABVX100%
-2.80%
IMNN - ABVX
58%
Loosely correlated
-2.97%
XENE - ABVX
38%
Loosely correlated
-1.74%
DYN - ABVX
37%
Loosely correlated
+0.94%
ZYME - ABVX
36%
Loosely correlated
-3.63%
IRON - ABVX
35%
Loosely correlated
-0.80%
More

DYN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DYN has been loosely correlated with RNA. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if DYN jumps, then RNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYN
1D Price
Change %
DYN100%
+0.94%
RNA - DYN
64%
Loosely correlated
-1.93%
RCUS - DYN
46%
Loosely correlated
-2.94%
VYGR - DYN
45%
Loosely correlated
-5.81%
IDYA - DYN
44%
Loosely correlated
-2.27%
NTLA - DYN
44%
Loosely correlated
-8.41%
More